Johnson & Johnson's talc lawsuit issues continue. Looming loss of exclusivity on JNJ's top drug can drag revenues. A string of revenue and EBIT misses does not inspire confidence. Technical analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback